Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

491
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
491
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

25
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
25
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

298
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
298
Actuarial Approach01:20

Actuarial Approach

330
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
330
Propagation of Uncertainty from Random Error00:59

Propagation of Uncertainty from Random Error

2.0K
An experiment often consists of more than a single step. In this case, measurements at each step give rise to uncertainty. Because the measurements occur in successive steps, the uncertainty in one step necessarily contributes to that in the subsequent step. As we perform statistical analysis on these types of experiments, we must learn to account for the propagation of uncertainty from one step to the next. The propagation of uncertainty depends on the type of arithmetic operation performed on...
2.0K
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

247
Body:The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
247

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular Testing in Primary Advanced or Recurrent Endometrial Cancer: A Cost-Effectiveness Analysis.

JCO precision oncology·2026
Same author

The effectiveness and value of cytisinicline for smoking cessation: A summary from the institute for clinical and economic review's midwest comparative effectiveness public advisory council.

Journal of managed care & specialty pharmacy·2026
Same author

The cost of implementing and sustaining the Massachusetts model.

The American journal of managed care·2026
Same author

Informing the US Medicare Drug Price Negotiation for Trelegy Ellipta and Breo Ellipta: Evaluating the Impact of Real-World Evidence.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same author

The effectiveness and value of therapies for spinal muscular atrophy.

Journal of managed care & specialty pharmacy·2026
Same author

Evaluating Long-Term Health Disparity Impacts of Clinical Algorithms Using a Patient-Level Simulation Framework.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2025
Same journal

Findings from the 2025 AMCP Foundation Symposium: Health Optimization 2.0.

Journal of managed care & specialty pharmacy·2026
Same journal

AMCP Market Insights: Managed care considerations in Barth syndrome.

Journal of managed care & specialty pharmacy·2026
Same journal

Association between comorbid depression, antidepressant adherence, and disease-modifying therapy adherence among Texas Medicaid patients with sickle cell disease.

Journal of managed care & specialty pharmacy·2026
Same journal

Incremental health care resource utilization, costs, and predictors of high costs in generalized myasthenia gravis.

Journal of managed care & specialty pharmacy·2026
Same journal

Real-world switching and switch-back patterns among patients transitioning from adalimumab to biosimilars in the United States (February 2023 to August 2025).

Journal of managed care & specialty pharmacy·2026
Same journal

The effectiveness and value of B-cell-directed therapies for the treatment of immunoglobulin A nephropathy.

Journal of managed care & specialty pharmacy·2026
See all related articles

Related Experiment Video

Updated: Feb 22, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.7K

Using Performance-Based Risk-Sharing Arrangements to Address Uncertainty in Indication-Based Pricing.

Kai Yeung1, Meng Li2, Josh J Carlson2

  • 11 Kaiser Permanente Washington Health Research Institute, Seattle, and Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle.

Journal of Managed Care & Specialty Pharmacy
|September 26, 2017
PubMed
Summary
This summary is machine-generated.

Outcomes guarantees can align drug prices with real-world effectiveness, offering a flexible approach to indication-based pricing (IBP) and reducing payer uncertainty.

More Related Videos

Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods
13:04

Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods

Published on: September 19, 2012

12.5K
A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research
09:35

A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research

Published on: August 16, 2017

18.4K

Related Experiment Videos

Last Updated: Feb 22, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.7K
Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods
13:04

Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods

Published on: September 19, 2012

12.5K
A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research
09:35

A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research

Published on: August 16, 2017

18.4K

Area of Science:

  • Health economics
  • Pharmaceutical pricing
  • Pharmacoeconomics

Background:

  • Rising pharmaceutical costs necessitate value-based pricing strategies.
  • Indication-based pricing (IBP) aims to align drug prices with efficacy across different uses.
  • Limitations of traditional IBP include reliance on clinical trial data, which may not reflect real-world effectiveness.

Purpose of the Study:

  • To explore the potential of outcomes guarantees to achieve indication-based prices aligned with real-world value.
  • To use a case study of trastuzumab for metastatic breast and advanced gastric cancers to illustrate this potential.

Main Methods:

  • Estimated costs and outcomes under traditional IBP and outcomes guarantee frameworks.
  • Calculated incremental cost-effectiveness ratios (ICERs) comparing treatment with and without trastuzumab.
  • Adjusted trastuzumab prices to meet a target ICER of $150,000 per quality-adjusted life-year for each indication and framework, using pivotal trial efficacy and observational study effectiveness data.

Main Results:

  • Traditional IBP required adjusting trastuzumab prices to $3.50/mg (breast cancer) and $0.93/mg (gastric cancer).
  • Outcomes guarantees required adjusting prices to $8.66/mg (breast cancer) and $0.20/mg (gastric cancer) based on real-world effectiveness.
  • Significant price adjustments were noted under both frameworks, highlighting differences between efficacy and effectiveness.

Conclusions:

  • Outcomes guarantee contracts can enable indication-specific pricing, similar to IBP.
  • These contracts can mitigate uncertainty surrounding drug effectiveness.
  • Outcomes guarantees offer a mechanism to better align drug payments with demonstrated real-world value.